SCHEMBL4338993

SCHEMBL4338993

CC(C)OC(Cc1cccc(CCOC(=O)Nc2ccc(Cl)cc2)c1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.45
CNR1 P21554 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 1/20 0.43
PPARG P37231 4/20 0.43
PPARA Q07869 4/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
RECQL P46063 1/20 0.41
PPARD Q03181 1/20 0.41
ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4339117 0.92 MGLL (0.54) MGLLSMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL4341714 0.91 MGLL (0.46) MGLLSMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL4348594 0.90 MEN1 (0.49) MGLLSMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL4336506 0.89 PPARA (0.48) SMN1; SMN2KMT2APPARGPPARAL3MBTL1
SCHEMBL4341184 0.89 LMNA (0.50) MGLLSMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL4331720 0.89 MAPK1 (0.52) MGLLSMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL4348243 0.88 PPARG (0.51) MGLLCNR1PPARGPPARAL3MBTL1
SCHEMBL4341815 0.87 FPR2 (0.45) MGLLCYP1A2CYP2C9PPARGPPARA
SCHEMBL4336950 0.86 MGLL (0.51) MGLLCNR1SMN1; SMN2MEN1KMT2A
SCHEMBL4333055 0.85 PPARG (0.42) SMN1; SMN2TSHRPPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-20040102634-A1 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-05-27 US disclosed
EP-1380562-A1 CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102634-A1 Carboxylic acid derivative and salt thereof GPR119, IRS1, SLC5A1 MGLL 3539/4885CNR1 75/4885SMN1; SMN2 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.